New Preclinical Study Finds Nicotinamide Riboside May Improve Immune Cell Function
LOS ANGELES--(BUSINESS WIRE)---- $CDXC #CellularHealth--ChromaDex Corp. (NASDAQ:CDXC) today highlighted a new study from Nature Immunology that found nicotinamide riboside (NR) helped energize tumor infiltrating T-cells (TILs) in samples extracted from mice. In a preclinical mouse model, NR was shown to improve T-cell function, which is a component of new cancer immunotherapies such as PD-1 and PDL-1 inhibitors. These findings lend further data to the potential role of NR in supporting healthy mitochondrial function. T-
